Nuclea Biotechnologies secured an additional $4.2 million in Series D financing, bringing the company's total for that round to $40.3 million. The Massachusetts-based firm will use some of the money to launch its fatty acid synthase assays and other diagnostic tests.
Diagnostic-test maker gets additional $4.2M funding boost
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||